Publications by authors named "B Arents"
Article Synopsis
- - The study evaluates the efficacy and safety of the new biologic medication lebrikizumab for treating atopic dermatitis in comparison to other systemic treatments, using a systematic network meta-analysis of clinical trials.
- - Data was gathered from various medical databases, focusing on trials that assessed treatment effects for at least 8 weeks in patients with moderate to severe atopic dermatitis, with analysis conducted using random-effects Bayesian methods.
- - Key outcomes measured include the improvement in eczema severity (using scales like EASI and POEM), safety indicators such as serious adverse events, and the ability of participants to achieve significant improvements in their condition.
Background: Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, as current evidence is of low certainty. Our aim is to assess the short-term and long-term (cost-)effectiveness and safety of NB-UVB in adult AE patients by performing a pragmatic, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial.
View Article and Find Full Text PDFArticle Synopsis
- Telemedicine has become more popular for providing remote healthcare, especially after the COVID-19 pandemic, and may serve as an alternative for routine visits for patients with chronic skin conditions.
- A systematic review of 11 studies (including RCTs) indicates that telemedicine appears to be comparable to in-person consultations for managing chronic inflammatory skin diseases like psoriasis and atopic dermatitis, particularly regarding patient quality of life.
- Despite encouraging results about telemedicine's benefits, such as cost-effectiveness and convenience, further extensive research is needed to solidify these findings and address any uncertainties.
Italian S3-Guideline on the treatment of Atopic Eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA).
Ital J Dermatol Venerol
June 2024
Article Synopsis
- A new guideline for atopic eczema was published in two parts in August and September 2022, based on the EuroGuiDerm standards, following extensive consensus conferences with experts from twelve European countries.
- The guideline incorporates recent evidence on new systemic medications, with an update released in October 2022.
- Italian dermatological societies adapted the original EuroGuiDerm guideline for the Italian healthcare context, adding specific notes to highlight regulations and recommendations from the Italian Ministry of Health and regional authorities.
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual.
View Article and Find Full Text PDF